Key facts
- It has raised $13.7M; the latest was Early Stage VC ($13.7M) in Jan 2025.
- Notable investors include Goldport Capital, Changzhou Hi-tech Group, The Hina Group, Dymind Biotech, Shenzhen Weiguang — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Liying Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Liying Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Liying Biotechnology
Developer of protein biological products designated for the innovation and development of protein biological industry. The company focuses on the research and development of high-level and high-quality protein biological products, it uses the analysis of protein structure data or AI prediction, and has realized rapid optimization of protein functions to obtain protein raw materials with excellent performance, its technology can be widely used in vitro diagnostic reagents, protein drugs, biological enzyme preparations, mRNA vaccine design, etc., providing global customers with better biological products and services.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Website
- lybio.com/
- Ownership
- Privately Held (backing)
Liying Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Liying Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Liying Biotechnology in its N-PORT filings yet. We sweep new filings monthly.